Staff Events

Aquaporin-4-specific T cells and gut microbiota in neuromyelitis optica

Scott Zamvil

Dr Scott Zamvil
University of California, San Francisco (UCSF)


Bio

Scott S. Zamvil, M.D., Ph.D., is a clinical neurologist and immunologist at the University of California, San Francisco (UCSF) who is specializes in the care of patients with multiple sclerosis (MS) and neuromyelitis optica (NMO) and is devoted to developing novel treatments for these autoimmune diseases. His novel research into the use of statins to fight MS was featured on the cover of Newsweek and reported by the New York Times, CNN, and National Public Radio. Dr. Zamvil was the Principal Investigator for the first placebo-controlled trial testing a statin drug in multiple sclerosis. In his basic science research, Dr. Zamvil investigates the role of B cells and other antigen presenting cells in the activation of T cells that recognize myelin autoantigens and aquaporin-4 (AQP4), the autoantigen in NMO. He has publications in Nature, Nature Medicine, The Journal of Clinical Investigation, The Journal of Experimental Medicine, Annals of Neurology and The Journal of Immunology.

Dr. Zamvil received his M.D. and Ph.D. in Medical Microbiology and Immunology from Stanford University, California, where he trained in internal medicine. He completed a residency in neurology at Brigham and Women's Hospital, Boston, Massachusetts, subsequently joining the Harvard neurology faculty. In 1994, Dr. Zamvil was named a NMSS Harry Weaver Science Scholar. Since 1998, he has been on neurology faculty at UCSF where he is Professor of Neurology. Dr. Zamvil has joint appointments as a faculty member in the Program in Immunology and the Biomedical Sciences Graduate Program. In 2014, Dr. Zamvil was named the Donnie Smith Chair in Multiple Sclerosis Research.

Dr. Zamvil is Deputy Editor of Neurology, Neuroimmunology and Neuroinflammation (N2) and has also served on the Editorial Boards of The Journal of Clinical Investigation, The Journal of Immunology, Neurotherapeutics and The Journal of Neurological Sciences. His research is funded by the National Multiple Sclerosis Society (NMSS), National Institutes of Health (NIH), Guthy Jackson Charitable Foundation, Maisin Foundation, Teva Pharmaceuticals and Biogen Idec. Dr. Zamvil is currently serving a third term on the NMSS Peer Review Research Grant Committee, and was previously a Charter Member of the NIH Clinical Neuroimmunology and Brain Tumors (CNBT) grant review committee. He also serves on the Clinical Advisory Board for the Myelin Repair Foundation, the Advisory Board of the American Academy on Treatment and Research in Clinical Trials (ACTRIMS), and is an elected Board Member of the International Society for Neuroimmunology (ISNI)